The trading price of TransCode Therapeutics Inc (NASDAQ:RNAZ) closed higher on Monday, April 14, and closing at $0.41, 1.49% higher than its previous close.
Traders who pay close attention to intraday price movement should know that it fluctuated between $0.3636 and $0.4199. In examining the 52-week price action we see that the stock hit a 52-week high of $66.33 and a 52-week low of $0.34. Over the past month, the stock has lost -47.29% in value.
TransCode Therapeutics Inc, whose market valuation is $9.57 million at the time of this writing, is expected to release its quarterly earnings report on 2024-Nov-13. Investors’ optimism about the company’s current quarter earnings report is understandable. Analysts have predicted the quarterly earnings per share to grow by -3.21 per share this quarter, however they have predicted annual earnings per share of -4.76 for current year and -4.37 for next year.
Analysts have forecast the company to bring in revenue of 300k for the current quarter, with the likely lows of 300k and highs of 300k. From the analysts’ viewpoint, the consensus estimate for the company’s annual revenue is 300k.
On the technical side, indicators suggest RNAZ has a 100% Sell on average for the short term. According to the data of the stock’s medium term indicators, the stock is currently averaging as a 100% Sell, while an average of long term indicators suggests that the stock is currently 100% Sell.
A quick review shows that RNAZ’s price is currently -27.83% off the SMA20 and -88.69% off the SMA50. The RSI metric on the 14-day chart is currently showing 28.06, and weekly volatility stands at 16.51%. When measured over the past 30 days, the indicator reaches 22.36%. TransCode Therapeutics Inc (NASDAQ:RNAZ)’s beta value is currently sitting at 1.52, while the Average True Range indicator is currently displaying 0.31.
To see how TransCode Therapeutics Inc stock has been performing in comparison to its peers in the industry, here are the numbers: RNAZ stock’s performance was 1.49% in the latest trading, and -98.06% in the past year.
An evaluation of the daily trading volume of TransCode Therapeutics Inc (NASDAQ:RNAZ) indicates that the 3-month average is 7.26 million. However, this figure has increased over the past 10 days to an average of 2.86.
Currently, records show that 23.34 million of the company’s shares remain outstanding. The insiders hold 10.11% of outstanding shares, whereas institutions hold 0.78%. The stats also highlight that short interest as of 2025-03-31, stood at 2.55 million shares, resulting in a short ratio of 0.17 at that time. From this, we can conclude that short interest is 36689.00 of the company’s total outstanding shares. It is noteworthy that short shares in March were up slightly from the previous month’s figure, which was 0.54 million. However, since the stock’s price has seen -87.83% year-to-date, investors’ interest is likely to be reignited due to its potential to move even lower.
